- Home
- IDAI vs SNGX Comparison
IDAI vs SNGX Comparison
Compare IDAI & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDAI
- SNGX
- Stock Information
- Founded
- IDAI 2016
- SNGX 1987
- Country
- IDAI United States
- SNGX United States
- Employees
- IDAI N/A
- SNGX N/A
- Industry
- IDAI Computer Software: Prepackaged Software
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- IDAI Technology
- SNGX Health Care
- Exchange
- IDAI Nasdaq
- SNGX Nasdaq
- Market Cap
- IDAI 5.5M
- SNGX 6.1M
- IPO Year
- IDAI N/A
- SNGX 1987
- Fundamental
- Price
- IDAI $1.88
- SNGX $2.21
- Analyst Decision
- IDAI
- SNGX
- Analyst Count
- IDAI 0
- SNGX 0
- Target Price
- IDAI N/A
- SNGX N/A
- AVG Volume (30 Days)
- IDAI 73.9K
- SNGX 29.1K
- Earning Date
- IDAI 05-13-2025
- SNGX 05-09-2025
- Dividend Yield
- IDAI N/A
- SNGX N/A
- EPS Growth
- IDAI N/A
- SNGX N/A
- EPS
- IDAI N/A
- SNGX N/A
- Revenue
- IDAI $3,082,348.00
- SNGX $119,371.00
- Revenue This Year
- IDAI $66.11
- SNGX N/A
- Revenue Next Year
- IDAI N/A
- SNGX N/A
- P/E Ratio
- IDAI N/A
- SNGX N/A
- Revenue Growth
- IDAI N/A
- SNGX N/A
- 52 Week Low
- IDAI $0.15
- SNGX $1.83
- 52 Week High
- IDAI $8.96
- SNGX $14.88
- Technical
- Relative Strength Index (RSI)
- IDAI 38.52
- SNGX 42.26
- Support Level
- IDAI $1.73
- SNGX $2.25
- Resistance Level
- IDAI $2.16
- SNGX $2.28
- Average True Range (ATR)
- IDAI 0.26
- SNGX 0.11
- MACD
- IDAI 0.01
- SNGX -0.01
- Stochastic Oscillator
- IDAI 17.31
- SNGX 35.48
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).